---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/39798502.md"
description: "Zai Lab's commercialization and licensing model in China has seen multiple products included in the national reimbursement drug list (NRDL), with high visibility for revenue growth in 2026.JD Health, a leader in internet healthcare, continues to see growth in monthly active users and online penetration of prescription drugs. Improved consumer sentiment post-ceasefire is beneficial for platform transaction volume.Insilico Medicine is a globally representative company in AI-driven drug discovery, with pipeline progress being a short-term catalyst. Its latest funding round valued the company at over $600 million, and it is currently in a window of valuation re-rating as it transitions from an AI tool provider to a clinical-stage pipeline company."
datetime: "2026-04-09T11:38:02.000Z"
locales:
  - [en](https://longbridge.com/en/topics/39798502.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/39798502.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/39798502.md)
author: "[Profit长期主义](https://longbridge.com/en/profiles/16445495.md)"
---

# Zai Lab's commercialization and licensing model in…


### Related Stocks

- [09688.HK](https://longbridge.com/en/quote/09688.HK.md)
- [ZLAB.US](https://longbridge.com/en/quote/ZLAB.US.md)
- [06618.HK](https://longbridge.com/en/quote/06618.HK.md)
- [86618.HK](https://longbridge.com/en/quote/86618.HK.md)
- [03696.HK](https://longbridge.com/en/quote/03696.HK.md)